Investigational drug · Phase 3
iltamiocel
Also called: AMDC-USR
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Stress Urinary Incontinence, Fecal Incontinence.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "iltamiocel"
First trial start
2019
Apr 23, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "iltamiocel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Stress Urinary Incontinence
- Fecal Incontinence
Approved drugs for the same conditions: Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "iltamiocel" as an intervention, largest first.
- Autologous Muscle Derived Cells for Female Urinary Sphincter RepairPivotal-lookingCompleted
Cook MyoSiteIndustry
NCT01893138 · 311 participants · Start Nov 21, 2013 · Primary completion Nov 1, 2019
Drug: Iltamiocel · For: Stress Urinary Incontinence
Sites: Phoenix, Arizona; Agoura Hills, California; Los Angeles, California · 29 sites in all
- Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric InjuryPivotal-lookingActive, not recruiting
Cook MyoSiteIndustry
NCT05776277 · 200 participants (planned) · Start Mar 21, 2024 · Primary completion Dec 2026
Drug: Iltamiocel · For: Fecal Incontinence
Sites: La Jolla, California; Orange, California; San Francisco, California · 25 sites in all
- Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress IncontinencePivotal-lookingActive, not recruiting
Cook MyoSiteIndustry
NCT03104517 · 96 participants (planned) · Start Apr 23, 2019 · Primary completion Jun 11, 2026
Drug: AMDC-USR (iltamiocel) · For: Stress Urinary Incontinence
Sites: Tucson, Arizona; La Mesa, California; Los Angeles, California · 21 sites in all
Cook MyoSiteIndustry
NCT01600755 · 53 participants · Start Mar 28, 2013 · Primary completion Oct 27, 2021
Drug: Iltamiocel · For: Fecal Incontinence
Sites: Vancouver, Canada; London, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Iltamiocel Autologous Cell Therapy for the Treatment of Female Stress Urinary Incontinence: A Double-Blind, Randomized, Stratified, Placebo-Controlled Trial.
Kaufman MR, Goldman HB, Chermansky CJ, et al. · Neurourol Urodyn 2024
- Safety and Efficacy of Iltamiocel Cellular Therapy for the Treatment of Fecal Incontinence. Results of a Phase 1/2 Study.
Knowles CH, Canestrari E, Jankowski RJ, et al. · Ann Surg 2023
- Contemporary application of autologous muscle-derived cells for urinary sphincter regeneration.
Kaufman MR · World J Urol 2020
- A double-blind, randomized, placebo-controlled clinical trial evaluating the safety and efficacy of autologous muscle derived cells in female subjects with stress urinary incontinence.
Jankowski RJ, Tu LM, Carlson C, et al. · Int Urol Nephrol 2018
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.